Charcot-Marie-Tooth Market to Reach $4.5 Billion by 2036 as Genetic Testing Lifts Demand
Updated
Updated · futuremarketinsights.com · Aug 18
Charcot-Marie-Tooth Market to Reach $4.5 Billion by 2036 as Genetic Testing Lifts Demand
1 articles · Updated · futuremarketinsights.com · Aug 18
Summary
$4.5 billion is the projected 2036 size of the Charcot-Marie-Tooth market, up from $1.6 billion in 2026, implying a 10.8% compound annual growth rate.
Genetic confirmation and long-term care needs are driving that growth, as subtype-specific diagnosis steers patients into rehabilitation plans, specialist follow-up and clinical trial referral.
Supportive therapy is expected to hold 39% of 2026 treatment demand because no approved therapy reverses inherited peripheral-nerve damage, leaving rehabilitation and orthotic care as the mainstay.
CMT1 is forecast to account for 43% of application demand and hospitals 38% of end-user demand in 2026, reflecting the concentration of genetically defined cases in multidisciplinary centers.
Development still faces slow disease progression, genetic heterogeneity and difficult peripheral-nerve delivery, even as companies including Novartis, ENCell, NMD Pharma and Vanda advance targeted programs.